Market-Moving News for June 7th
$BCDA
$GME
$ODD
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Electronics Distribution
Consumer Discretionary
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 9/24/2025 | $78.00 | Buy | Jefferies | |
| 8/28/2025 | $72.00 | Buy | Needham | |
| 1/31/2025 | $55.00 | Overweight | Analyst | |
| 12/13/2024 | $48.00 | Neutral | Goldman | |
| 4/4/2024 | $57.00 | Outperform | Evercore ISI | |
| 10/4/2023 | $60.00 → $37.00 | Neutral → Buy | BofA Securities | |
| 10/3/2023 | $54.00 | Hold → Buy | Truist | |
| 8/15/2023 | $57.00 | Equal Weight | Barclays |
4 - BioCardia, Inc. (0000925741) (Issuer)
4 - GameStop Corp. (0001326380) (Issuer)
4 - GameStop Corp. (0001326380) (Issuer)
SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it has completed its Pre-Submission to FDA under its Q-Submission program for the approval of its Helix Transendocardial Delivery Catheter ("Helix") for intramyocardial therapeutic and diagnostic agent delivery. The data supporting safety and effectiveness for the Helix Pre-Submission is from fifteen well-controlled clinical trials of cell and gene therapy delivery to the heart using Helix, where patients were enrolled in three primary cardiac clinical indications. The Helix
SUNNYVALE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced echocardiography data for the CardiAMP Cell Therapy for the treatment of heart failure has been accepted for Late Breaking Clinical Trial Oral Presentation at the Technology and Heart Failure Therapeutics (THT) Meeting, which takes place March 2-4 in Boston, Massachusetts. On behalf of the CardiAMP HF investigators, the presentation will be made by Dr. Amish Raval, M.D., Professor of Medicine at UW School of Medicine and Public Health and CardiAMP HF Trial National Co-Principal
Return to Silent Hill Hits Theaters Nationwide on January 23 – Buy Tickets Now LOS ANGELES and GRAPEVINE, Texas, Jan. 14, 2026 /PRNewswire/ -- Cineverse (NASDAQ:CNVS), a next generation entertainment studio, and GameStop Corp. (NYSE:GME), are pulling out all the stops in anticipation of the January 23 wide theatrical release of Return to Silent Hill (returntosilenthillmovie.com). The two companies are collaborating on an immersive marketing campaign for the new film, based on the visionary video game, SILENT HILL 2. Since January 7, fans who visit a participating GameStop ca
Jefferies initiated coverage of ODDITY Tech Ltd. with a rating of Buy and set a new price target of $78.00
Needham initiated coverage of ODDITY Tech Ltd. with a rating of Buy and set a new price target of $72.00
Analyst initiated coverage of ODDITY Tech Ltd. with a rating of Overweight and set a new price target of $55.00
SCHEDULE 13G/A - Oddity Tech Ltd (0001907085) (Subject)
8-K - BioCardia, Inc. (0000925741) (Filer)
SCHEDULE 13G/A - Oddity Tech Ltd (0001907085) (Subject)
4 - BioCardia, Inc. (0000925741) (Issuer)
4 - GameStop Corp. (0001326380) (Issuer)
4 - GameStop Corp. (0001326380) (Issuer)
Third quarter net revenue of $148 million, up 24% year-over-yearNine-month net revenue of $657 million, up 26% year-over-yearThird quarter adjusted EBITDA of $29 millionNine-month adjusted EBITDA of $151 millionThird quarter net income of $18 million and third quarter adjusted net income of $25 millionNine-month operating cash flow of $93 million and free cash flow of $90 million NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. (NASDAQ:ODD) today announced its financial results for the third quarter ended September 30, 2025. "ODDITY delivered strong third quarter results, including financial performance that once again exceeded our guidance across revenue, profit, and earning
SUNNYVALE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the third quarter of 2025 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2025 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session. "This quarter's $6 million financing is actively supporting approvability discussions of CardiAMP
SUNNYVALE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three and nine months ended September 30, 2025 by conference call on Wednesday, November 12, 2025 at 4:30 PM EDT. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10204565/1005a9b26d8. Please note that registered participants will receive their dial-in number upon registration. F
Return to Silent Hill Hits Theaters Nationwide on January 23 – Buy Tickets Now LOS ANGELES and GRAPEVINE, Texas, Jan. 14, 2026 /PRNewswire/ -- Cineverse (NASDAQ:CNVS), a next generation entertainment studio, and GameStop Corp. (NYSE:GME), are pulling out all the stops in anticipation of the January 23 wide theatrical release of Return to Silent Hill (returntosilenthillmovie.com). The two companies are collaborating on an immersive marketing campaign for the new film, based on the visionary video game, SILENT HILL 2. Since January 7, fans who visit a participating GameStop ca
SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the appointment of Farhan Shahab as Vice President of Quality. Mr. Shahab brings over 25 years of experience to BioCardia in similar executive roles. Mr. Shahab joins BioCardia from Welldoc (a digital health company focused on chronic disease management), where he served as Vice President of Quality and Regulatory. Prior to that, he served as Senior Director of Regulatory Affairs and Quality Assurance at Intuity Medical (a blood glucose monitoring device company), and as Dir
Highlights Mr. Evans Is a Proven Public Company CFO and Value Creator, Who Has Successfully Worked Alongside CEO Kurt Wolf While on the Boards of Pitney Bowes and GameStop Notes Mr. Evans Has Stepped Down as a Director, and Peter Brimm, a Seasoned Investor and Finance Expert, Has Been Appointed as an Independent Member of the Pitney Bowes Board Pitney Bowes Inc. (NYSE:PBI) ("Pitney Bowes" or the "Company"), a technology-driven products and services company that provides SaaS shipping solutions, mailing innovation, and financial services to clients around the world, today announced the appointment of Paul Evans as the Company's next EVP, Chief Financial Officer ("CFO") and Treasurer, eff
SC 13G/A - Oddity Tech Ltd (0001907085) (Subject)
SC 13G/A - Oddity Tech Ltd (0001907085) (Subject)
SC 13G - Oddity Tech Ltd (0001907085) (Subject)
